Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®

Reuters

2025/09/12

Uni-Bio Science Group and <a href="https://laohu8.com/S/688136">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®

Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566218927"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566218927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566218927?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566218927","market":"us","top_or_hot":-1,"title":"Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group and <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group and <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL95x3Vt:1","article_id":"2566218927","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566218927","pubTimestamp":1757669282,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai  in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK1161":"生物科技","00690":"联康生物科技集团","BK0239":"医药制造"},"translate_title":"Uni-Bio Science Group与科兴生物制药结成战略联盟，全球化骨质疏松症治疗博古泰®","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":0.9,"00690":0.9},"content_text":"Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    \n\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}